Top

Published in:

26-12-2023 | Denosumab | Letter to the Editor

Transient osteoporosis of the hip following discontinuation of denosumab and switch to alendronate treatment

Authors: Polyzois Makras, Maria P. Yavropoulou, Athanasios D. Anastasilakis, Athanasios Papatheodorou, Christos Tekedis, Socrates E. Papapoulos

Published in: Osteoporosis International | Issue 4/2024

Excerpt

To the Editor, …

Paraskevopoulos K, Keskinis A, Vasios IS, Makiev KG, Tilkeridis K, Drosos GI, Ververidis AN (2023) Comparison of various treatment modalities for the management of bone marrow edema syndrome/transient osteoporosis in men and non-pregnant women: a systematic review. Osteoporos Int 34:269–290CrossRefPubMed

Paraskevopoulos K, Keskinis A, Vasios IS, Makiev KG, Tilkeridis K, Drosos GI, Ververidis AN (2023) Letter to the editor regarding “Comparison of various treatment modalities for the management of bone marrow edema syndrome or transient osteoporosis in men and nonpregnant women: a systematic review.” Osteoporos Int 34:817–818CrossRefPubMed

Varenna M, Zuchhi F, Binelli L, Failoni S, Gallazzi M, Sinigaglia L (2002) Intravenous pamidronate in the treatment of transient osteoporosis of the hip. Bone 31:96–101CrossRefPubMed

Berger CA, Krȍner AH, Minai-Pour MB, Ogris E (2003) Biochemical markers of bone metabolism in bone marrow edema syndrome of the hip. Bone 33:346–351CrossRefPubMed

Emad Y, Ragab Y, El-Shaarawy N, Rasker JJ (2012) Transient osteoporosis of the hip, complete resolution after treatment with alendronate as observed by MRI description of eight cases and review of the literature. Clin Rheumatol 31:1641–1647CrossRefPubMed

McCarthy EF (1998) The pathology of transient regional osteoporosis. Iowa Orthop J 18:35–42PubMedPubMedCentral

Dohke T, Iba K, Hanaka M, Kanaya K, Abe Y, Okazaki S, Yamashita T (2017) Regional osteoporosis due to osteoclast activation as a trigger for the pain-like behaviors in tail-suspended mice. J Orthop Res 35:1226–1236CrossRefPubMed

Makras P, Appelman-Dijkstra NM, Papapoulos SE, van Wissen S, Winter EM, Polyzos SA, Yavropoulou MP, Anastasilakis AD (2021) The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab 106:e4155–e4162CrossRefPubMed

Title: Transient osteoporosis of the hip following discontinuation of denosumab and switch to alendronate treatment
Authors: Polyzois Makras
Maria P. Yavropoulou
Athanasios D. Anastasilakis
Athanasios Papatheodorou
Christos Tekedis
Socrates E. Papapoulos
Publication date: 26-12-2023
Publisher: Springer London
Keywords: Denosumab
Denosumab
Osteoporosis
Osteoporosis
Published in: Osteoporosis International / Issue 4/2024
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-023-07000-5

ERS Congress 2024

Springer Medicine

Transient osteoporosis of the hip following discontinuation of denosumab and switch to alendronate treatment

Excerpt

ERS Congress 2024

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2024

Geographic variation in bone mineral density and prevalent fractures in the Canadian longitudinal study on aging

Higher risk of osteoporosis in adult-onset asthma than childhood-onset asthma: from genetic and prospective evidence

Utility of MRI-based vertebral bone quality scores and CT-based Hounsfield unit values in vertebral bone mineral density assessment for patients with diffuse idiopathic skeletal hyperostosis

Opportunistically identifiable vertebral fractures on routine radiological imaging predict mortality: observational cohort study

Systematic review and meta-analysis of preoperative predictors for early mortality following hip fracture surgery

Efficacy of denosumab in the treatment of hypercalcemic renal dysfunction in sarcoidosis: a case report